VEA Stock UPDATES EAFE ETF MSCI Vanguard (VEA) 41.27 09/17/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
EAFE ETF MSCI Vanguard (VEA) 41.27 $VEA

Vanguard Poised to Become 2nd Biggest ETF Issuer - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 9:00AM CDT
Thanks to the low cost model from Vanguard, the company is now almost the second biggest sponsor of ETFs, by AUM, in the U.S.

Vanguard MSCI EAFE ETF Set to Possibly Rebound After Yesterday's Selloff of 1.23%
Comtex SmarTrend(R) - Tue Aug 05, 5:47PM CDT
Vanguard MSCI EAFE ETF (NYSE:VEA) traded in a range yesterday that spanned from a low of $40.90 to a high of $41.30. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $41.25 on volume of 3.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

ETF Asset Report for the First Half of 2014 - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 7:00AM CDT
These ETFs led the way in terms of inflows and outflows for the first half of 2014.

Top Ranked Foreign Large Cap ETF in Focus: FNDF - ETF News And Commentary
Zacks Equity Research - ZACKS - Fri Jun 20, 9:00AM CDT
If you are seeking exposure to the large cap market beyond American shores, consider this ETF from Schwab.

Can Online Services Replace Merrill Lynch?
at The Street - Thu Mar 06, 9:48AM CST
Perhaps. Computerized systems are building low-cost portfolios and costing investors less.

After Yesterday's Decline of 2.03%, Vanguard MSCI EAFE ETF Offers Investors Better Value
Comtex SmarTrend(R) - Mon Mar 03, 5:18PM CST
Vanguard MSCI EAFE ETF (NYSE:VEA) traded in a range yesterday that spanned from a low of $40.88 to a high of $41.26. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $41.46 on volume of 4.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

SmarTrend Watching for Potential Pullback in Shares of Vanguard MSCI EAFE ETF After 1.09% Gain
Comtex SmarTrend(R) - Tue Sep 10, 4:54PM CDT
Vanguard MSCI EAFE ETF (NYSE:VEA) traded in a range yesterday that spanned from a low of $38.90 to a high of $39.06. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $38.66 on volume of 4.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

European ETFs: A Surge in Popularity? - ETF News And Commentary
Eric Dutram - ZACKS - Wed Sep 04, 9:01AM CDT
Four European ETFs (and two mid cap ETFs) are leading the way for inflows.

Look for Shares of Vanguard MSCI EAFE ETF to Potentially Rebound after Yesterday's 1.15% Sell Off
Comtex SmarTrend(R) - Fri Aug 30, 3:52PM CDT
Vanguard MSCI EAFE ETF (NYSE:VEA) traded in a range yesterday that spanned from a low of $36.82 to a high of $37.10. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $37.08 on volume of 3.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

After Yesterday's Rally of 1.01% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Jul 01, 6:12PM CDT
Vanguard MSCI EAFE ETF (NYSE:VEA) traded in a range yesterday that spanned from a low of $35.88 to a high of $36.09. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of $35.81 on volume of 4.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Watch for Vanguard MSCI EAFE ETF to Potentially Rebound After Falling 1.52% Yesterday
Comtex SmarTrend(R) - Thu May 23, 4:25PM CDT
Vanguard MSCI EAFE ETF (NYSE:VEA) traded in a range yesterday that spanned from a low of $37.73 to a high of $38.36. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $38.79 on volume of 3.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

DIM, SAI, AVAV, EIG, VEA, IVZ Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Mon Apr 29, 5:48AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of WisdomTree International MidCap Dividend Fund (NYSE IM), SAIC Inc (NYSE:SAI), AEROVIRONMENT, INC. (NASDAQ:AVAV), EMPLOYERS HOLDINGS INC (NYSE:EIG), Vanguard MSCI EAFE ETF (NYSE:VEA), Invesco Ltd (NYSE:IVZ) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:

SmarTrend Watching for Potential Rebound in Shares of Vanguard MSCI EAFE ETF After 1.18% Loss
Comtex SmarTrend(R) - Mon Apr 01, 4:08PM CDT
Vanguard MSCI EAFE ETF (NYSE:VEA) traded in a range yesterday that spanned from a low of $35.92 to a high of $36.26. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $36.01 on volume of 5.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean revision.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 62

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 271

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 718

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 135

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 255

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 410

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 105

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 325

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 139

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 190

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Kearney's 2025 Global Cities Report Insights

Updated Category News Views 654

Global Cities Adapt to New Challenges and Emergence Global cities hold steady at the top as new hubs surge forward Top cities reaffirm their dominance in the Global Cities Index, showcasing remarkable resilience amidst global changes and uncertainties. The Global Cities Outlook indicates a noticeable shift as traditional leaders face turbulence, while emerging Gulf and...

Continue Reading
Vacca Family Law Group Enhances Support for Peaceful Divorce

Updated Category News Views 255

Empowering Families Through Non-Adversarial Divorce Solutions Families navigating the challenging process of separation now have renewed access to considerate and non-confrontational divorce options. Vacca Family Law Group has recently welcomed Attorney and Mediator Wendy Reimer, who brings nearly two decades of experience in family law and a strong background in...

Continue Reading
Ingredion Delivers Impressive Q3 Results, Upgrades Outlook

Updated Category News Views 55

Ingredion's Strong Performance in the Third Quarter Ingredion Incorporated (NYSE: INGR) has reported remarkable results for the third quarter of 2024, showcasing a noteworthy surge in both operating income and earnings per share (EPS). The global leader in ingredient solutions for the food and beverage industry achieved a stunning 26% increase in reported operating income...

Continue Reading
Insight into Learning Technologies Group Plc's Disclosure Mechanism

Updated Category News Views 193

Understanding the Public Opening Position Disclosure Process In the complex world of financial securities, understanding the disclosure requirements can feel daunting. However, the process outlined by the Takeover Code, particularly Rule 8.3, provides a structured approach for individuals and entities holding significant interests in relevant securities. This rule is...

Continue Reading
Avidity Biosciences Set to Inspire with Latest Presentations

Updated Category News Views 191

Avidity Biosciences' Key Presentations at the MDA Conference Avidity Biosciences, Inc. (Nasdaq: RNA), a pioneer in RNA therapeutics, is poised to make a significant impact at the upcoming Clinical and Scientific Conference organized by the Muscular Dystrophy Association (MDA). The event will showcase the latest advancements in the field and highlight groundbreaking...

Continue Reading